Early hematopoietic stem cell transplantation in a patient with severe mucopolysaccharidosis II: A 7 years follow-up

Molecular Genetics and Metabolism Reports

Volumn 12, Issue , 2017, Pages 62-68

  Barth, Anneliese L ^a   de Magalhães, Tatiana S P C ^a   Reis, Ana Beatriz R ^a   de Oliveira, Maria Lucia ^b   Scalco, Fernanda B ^b   Cavalcanti, Nicolette C ^a   Silva, Daniel S e ^a   Torres, Danielle A ^a   Costa, Alessandra A P ^a   Bonfim, Carmem ^c   Giugliani, Roberto ^d   Llerena, Juan C ^a   Horovitz, Dafne D G ^a  

^a INSTITUTO OSWALDO CRUZ   (Brazil)

^b FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c FEDERAL UNIVERSITY OF PARANÁ   (Brazil)

^d HOSPITAL DE CLÍNICAS DE PORTO ALEGRE   (Brazil)

Author keywords

Hematopoietic stem cell transplantation; Mucopolysaccharidosis; Neurocognition

Indexed keywords

AMPICILLIN; BUSULFAN; CEFOTAXIME; CEFTRIAXONE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN; GENTAMICIN; GLYCOSAMINOGLYCAN; IDURONATE 2 SULFATASE; THYMOCYTE ANTIBODY;

ABSENCE OF SIDE EFFECTS; ARTICLE; CASE REPORT; CHILD; CHIMERA; COGNITION; DISEASE COURSE; DISEASE SEVERITY; FAMILY HISTORY; FOLLOW UP; GRAFT VERSUS HOST REACTION; HEARING IMPAIRMENT; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; HUNTER SYNDROME; INTELLIGENCE QUOTIENT; LANGUAGE; LEUKOCYTE; MALE; MOTOR PERFORMANCE; NERVE DEGENERATION; NEUROPSYCHOLOGICAL TEST; PHENOTYPE; SCHOOL CHILD; TREATMENT OUTCOME; UMBILICAL CORD BLOOD CELL; UPPER RESPIRATORY TRACT INFECTION; WECHSLER INTELLIGENCE SCALE FOR CHILDREN;

EID: 85020240310     PISSN: None     EISSN: 22144269     Source Type: Journal    
DOI: 10.1016/j.ymgmr.2017.05.010     Document Type: Article

References (32)

1. Neufeld, E.F., Muenzer, J., The Mucopolysaccharidoses. Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D., (eds.) The Metabolic and Molecular Bases of Inherited Disease, 8th ed, 2001, McGrow-Hill, New York, 3421–3452.
2. Holt, J.B., Poe, M.D., Escolar, M.L., Natural progression of neurological disease in mucopolisaccharidosis type II. Pediatrics 127 (2011), e1258–e1265.
3. Muenzer, J., Bodamer, O., Burton, B., Clarke, L., The role of enzyme replacement therapy in severe Hunter syndrome – an expert panel consensus. Eur. J. Pediatr. 171 (2012), 181–188.
4. Boado, R.J., Hui, E.K., Lu, J.Z., Sumbria, R.K., Pardridge, W.M., Blood-brain barrier molecular Trojan horse enables imaging of brain uptake of radioiodinated recombinant protein in the rhesus monkey. Bioconjug. Chem. 24 (2013), 1741–1749.
5. Lampe, C., Bosserhoff, A.K., Burton, B.K., Giugliani, R., Long-term experience with enzyme replacement therapy (ERT) in MPS II patients with a severe phenotype: an international case. J. Inherit. Metab. Dis. 37 (2014), 823–829.
6. Aldenhoven, M., Wynn, R.F., Orchard, P.J., O'Meara, A., Long-term outcome of Hurler syndrome patients after hematopoietic cell transplantation: an international multicenter study. Blood 125 (2015), 2164–2172.
7. Gosh, A., Miller, W., Orchard, P.J., Jones, S.A., Enzyme replacement therapy prior to hematopoietic stem cell transplantation in mucopolysaccharidosis type I: 10 year combined experience of 2 centers. Mol. Genet. Metab. 117 (2016), 373–377.
8. Poe, M.D., Chagnon, S.L., Escolar, M.L., Early treatment is associated with improved cognition in Hurler syndrome. Ann. Neurol. 76 (2014), 747–753.
9. de Ru, M.H., Boelens, J.J., Das, A.M., Jones, S.A., Enzyme replacement therapy and/or hematopoietic stem cell transplantation at diagnosis in patients with mucopolysaccharidosis type I: results of a European consensus procedure. Orphanet J. Rare Dis., 6, 2011, 55.
10. Wraith, J.E., Beck, M., Lane, R., van der Ploeg, A., Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase). Pediatrics 120 (2007), e37–e46.
11. Peters, C., Sterward, C.G., Hematopoietic cell transplantation for inherited metabolic diseases: an overview of outcomes and practice guidelines. Bone Marrow Transplant. 31 (2003), 229–239.
12. Prasad, V.K., Mendizabal, A., Parikh, S.H., Szabolcs, P., Unrelated donor umbilical cord blood transplantation for inherited metabolic disorders in 159 pediatric patients from a single center: influence of cellular composition of the graft on transplantation outcomes. Blood 112 (2008), 2979–2989.
13. Wynn, R.F., Wraith, J.E., Mercer, J., Improved metabolic correction in patients with lysosomal storage disease treated with hematopoietic stem cell transplant compared with enzyme replacement therapy. J. Pediatr. 154 (2009), 609–611.
14. Guffon, N., Bertrand, Y., Forest, I., Fouilhoux, A., Froissart, R., Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J. Pediatr. 154 (2009), 733–737.
15. Vellodi, A., Young, E., Cooper, A., Lidchi, V., Long-term follow-up following bone marrow transplantation for Hunter disease. J. Inherit. Metab. Dis. 22 (1999), 638–648.
16. Wang, J., Luan, Z., Jiang, H., Fang, J., Allogeneic hematopoietic stem cell transplantation in 34 pediatric cases of mucopolysaccharidosis – a 10-year report from China children transplant group. Biol. Blood Marrow Transplant. 22 (2016), 2104–2108.
17. Brusius-Facchin, A.C., Schwartz, I.V.D., Zimmer, C., Ribeiro, M.G., Muchopolysaccharidosis type II: identification of 30 novel mutation among Latin American patients. Mol. Genet. Metab. 111 (2014), 133–138.
18. Chiong, M.A.D., Canson, D.M., Abacan, M.A.R., Baluyot, M.M.P., Cordero, C.P., Silao, C.L.T., Clinical, biochemical and molecular characteristics of Filipino patients with mucopolysaccharidosis type II – Hunter syndrome. Orphanet J. Rare Dis., 12, 2017, 7.
19. Froissart, R., da Silva, I.M., Maire, I., Mucopolysaccharidosis type II: an update on mutation spectrum. Acta Paediatr. 96 (2007), 71–77.
20. Baldo, G., Matte, U., Artigalas, O., Schwartz, I.V., Placenta analysis of prenatally diagnosed patients reveals early GAG storage in mucopolysaccharidoses II and VI. Mol. Genet. Metab. 103 (2011), 197–198.
21. Lampe, C., Atherton, A., Burton, B.K., Descartes, M., Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age. JIMD Rep. 14 (2014), 99–113.
22. Souillet, G., Guffon, N., Maire, I., Pujol, M., Outcome of 27 patients with Hurler's syndrome transplanted either from related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 31 (2003), 1105–1117.
23. Silva, D.S., Barth, A.L., Esposito, A.C., Costa, A.A.P., Neurophysiological evaluation in cervical myelopathy in patients with mucopolysaccharidosis: the somatosensory and motor-evoked potentials. JIEMS, 2, 2014, S25.
24. McKinnis, E.J.R., Sulzbacher, S., Rutledge, J.C., Sanders, J., Scott, C.R., Bone marrow transplantation in Hunter syndrome. J. Pediatr. 129 (1996), 145–148.
25. Tanaka, A., Okuyama, T., Suzuki, Y., Sakai, N., Long-term efficacy of hematopoietic stem cell transplantation on brain involvement in patients with mucopolysaccharidosis type II: a nationwide survey in Japan. Mol. Genet. Metab. 107 (2012), 513–520.
26. Escolar, M., Poe, M., Rajan, D., Szabolcs, P., Longterm outcomes of patients receiving umbilical blood stem cell transplantation for MPS II. Mol. Genet. Metab. 108 (2012), S37–S38.
27. Papsin, B.C., Vellodi, A., Bailey, C.M., Ratcliffe, P.C., Leighton, S.E., Otologic and laryngologic manifestations of mucopolysaccharidosis after bone marrow transplantation. Otolaryngol. Head Neck Surg. 118 (1998), 30–36.
28. da Costa, V., O'Grady, G., Jackson, L., Kaylie, D., Raynor, E., Improvements in sensorineural hearing loss after cord blood transplant in patients with mucopolysaccharidosis. Arch. Otolaryngol. Head Neck Surg. 138 (2012), 1071–1076.
29. Cianfrone, G., Pentangelo, D., CianfroneF, Mazzei F., Pharmacological drugs inducing ototoxicity, vestibular symptoms and tinnitus: a reasoned and updated guide. Eur. Rev. Med. Pharmacol. Sci. 15 (2011), 601–636.
30. Tanjuakio, J., Suzuki, Y., Patel, P., Yasuda, E., Activities of daily living in patients with Hunter syndrome: impact of enzyme replacement therapy and hematopoietic stem cell transplantation. Mol. Genet. Metab. 114 (2015), 161–169.
31. Aldenhoven, M., Kurtzberger, J., Cord blood is the optimal graft source for the treatment of pediatric patients with lysosomal storage diseases: clinical outcomes and future directions. Cytotherapy 17 (2015), 765–774.
32. Wynn, R., Stem cell transplantation in inherited metabolic disorders. Hematology Am. Soc. Hematol. Educ. Program 2011 (2011), 285–291.